Spyros Domoxoudis1, Ioannis M Koukourakis1, Axiotis G Giakzidis1, Michael I Koukourakis2. 1. Department of Radiotherapy - Oncology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece. 2. Department of Radiotherapy - Oncology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece targ@her.forthnet.gr.
Abstract
BACKGROUND/AIM: Uterine sarcoma is an aggressive tumor associated with poor survival, compared to endometrioid carcinoma. Postoperative local radiotherapy and chemotherapy are controversial. PATIENTS AND METHODS: We report a retrospective analysis of 14 patients with uterine homologous type carcinosarcoma (9 patients) or leiomyosarcoma (5 patients), treated with postoperative 3D-conformal accelerated hypofractionated radiotherapy (2.7 Gy/fraction for 14 fractions followed by one fraction of 6-8 Gy dose to the vagina). Chemotherapy with cisplatin (50 mg/m2) and liposomal doxorubicin (20 mg/m2), was also administered bi-weekly for two cycles before and for three cycles during radiotherapy. RESULTS: Chemotherapy induced only grade 1 neutropenia or anemia in 4/14 (28.5%) and 5/14 (35.7%) of patients, respectively. Two patients (2/14, 14.2%) interrupted their radiotherapy for one and two weeks, respectively, due to grade II persistent diarrhea. Within a median of 58 months (range=8-137 months) of follow-up, none of the patients presented with loco-regional relapse. Two patients developed distant metastasis. CONCLUSION: Concurrent hypofractionated and accelerated chemo-radiotherapy (chemo-HypoAR) is feasible and provides excellent survival figures. Copyright
BACKGROUND/AIM: Uterine sarcoma is an aggressive tumor associated with poor survival, compared to endometrioid carcinoma. Postoperative local radiotherapy and chemotherapy are controversial. PATIENTS AND METHODS: We report a retrospective analysis of 14 patients with uterine homologous type carcinosarcoma (9 patients) or leiomyosarcoma (5 patients), treated with postoperative 3D-conformal accelerated hypofractionated radiotherapy (2.7 Gy/fraction for 14 fractions followed by one fraction of 6-8 Gy dose to the vagina). Chemotherapy with cisplatin (50 mg/m2) and liposomal doxorubicin (20 mg/m2), was also administered bi-weekly for two cycles before and for three cycles during radiotherapy. RESULTS: Chemotherapy induced only grade 1 neutropenia or anemia in 4/14 (28.5%) and 5/14 (35.7%) of patients, respectively. Two patients (2/14, 14.2%) interrupted their radiotherapy for one and two weeks, respectively, due to grade II persistent diarrhea. Within a median of 58 months (range=8-137 months) of follow-up, none of the patients presented with loco-regional relapse. Two patients developed distant metastasis. CONCLUSION: Concurrent hypofractionated and accelerated chemo-radiotherapy (chemo-HypoAR) is feasible and provides excellent survival figures. Copyright
Authors: E J Bernhard; E J Stanbridge; S Gupta; A K Gupta; D Soto; V J Bakanauskas; G J Cerniglia; R J Muschel; W G McKenna Journal: Cancer Res Date: 2000-12-01 Impact factor: 12.701
Authors: Nina L Jebsen; Øyvind S Bruland; Mikael Eriksson; Jacob Engellau; Ingela Turesson; Annika Folin; Clement S Trovik; Kirsten Sundby Hall Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-08 Impact factor: 7.038
Authors: Aaron H Wolfson; Mark F Brady; Thomas Rocereto; Robert S Mannel; Yi-Chun Lee; Robert J Futoran; David E Cohn; Olga B Ioffe Journal: Gynecol Oncol Date: 2007-09-05 Impact factor: 5.482
Authors: N S Reed; C Mangioni; H Malmström; G Scarfone; A Poveda; S Pecorelli; S Tateo; M Franchi; J J Jobsen; C Coens; I Teodorovic; I Vergote; J B Vermorken Journal: Eur J Cancer Date: 2008-04-02 Impact factor: 9.162
Authors: P Pautier; A Floquet; L Gladieff; E Bompas; I Ray-Coquard; S Piperno-Neumann; F Selle; C Guillemet; B Weber; R Largillier; F Bertucci; P Opinel; F Duffaud; A Reynaud-Bougnoux; C Delcambre; N Isambert; P Kerbrat; G Netter-Pinon; N Pinto; P Duvillard; C Haie-Meder; C Lhommé; A Rey Journal: Ann Oncol Date: 2012-11-08 Impact factor: 32.976